1
|
Chandrakumari S, Sivakumar D, Manikandan H, Gopalakrishnan M. Novel two step synthesis of bis/Mono 1-aryl-1H-tetrazole-5-carboxylic acid. SYNTHETIC COMMUN 2019. [DOI: 10.1080/00397911.2019.1610176] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
2
|
Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, Berger R, Goble SD, Morriello G, Harper B, Moyes CR, Shen DM, Wang L, Ball R, Fitzmaurice A, Frenkl T, Gichuru LN, Ha S, Hurley AL, Jochnowitz N, Levorse D, Mistry S, Miller RR, Ormes J, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Green S, Struthers M, Weber AE. Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder. J Med Chem 2016; 59:609-23. [DOI: 10.1021/acs.jmedchem.5b01372] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Scott D. Edmondson
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Cheng Zhu
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Nam Fung Kar
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Jerry Di Salvo
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Hiroshi Nagabukuro
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Beatrice Sacre-Salem
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Karen Dingley
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Richard Berger
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Stephen D. Goble
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Gregori Morriello
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Bart Harper
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Christopher R. Moyes
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Dong-Ming Shen
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Liping Wang
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Richard Ball
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Aileen Fitzmaurice
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Tara Frenkl
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Loise N. Gichuru
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Sookhee Ha
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Amanda L. Hurley
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Nina Jochnowitz
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Dorothy Levorse
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Shruty Mistry
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Randy R. Miller
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - James Ormes
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Gino M. Salituro
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Anthony Sanfiz
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Andra S. Stevenson
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Katherine Villa
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Beata Zamlynny
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Stuart Green
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Mary Struthers
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| | - Ann E. Weber
- Merck Research Laboratories, 2015 Galloping Hill Road, PO Box
539, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
3
|
|
4
|
Moyes CR, Berger R, Goble SD, Harper B, Shen DM, Wang L, Bansal A, Brown PN, Chen AS, Dingley KH, Di Salvo J, Fitzmaurice A, Gichuru LN, Hurley AL, Jochnowitz N, Miller RR, Mistry S, Nagabukuro H, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Struthers M, Weber AE, Edmondson SD. Design, Synthesis, and Evaluation of Conformationally Restricted Acetanilides as Potent and Selective β3Adrenergic Receptor Agonists for the Treatment of Overactive Bladder. J Med Chem 2014; 57:1437-53. [DOI: 10.1021/jm4017224] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Christopher R. Moyes
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Richard Berger
- Early Development and Discovery Sciences, Merck and Co., Inc., 770 Sumneytown Pike, West Point, Pennsylvania 19486, United States
| | - Stephen D. Goble
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Bart Harper
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Dong-Ming Shen
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Liping Wang
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Alka Bansal
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Patricia N. Brown
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Airu S. Chen
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Karen H. Dingley
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Jerry Di Salvo
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Aileen Fitzmaurice
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Loise N. Gichuru
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Amanda L. Hurley
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Nina Jochnowitz
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Randall R. Miller
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Shruty Mistry
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Hiroshi Nagabukuro
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Gino M. Salituro
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Anthony Sanfiz
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Andra S. Stevenson
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Katherine Villa
- Early Development and Discovery Sciences, Merck and Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States
| | - Beata Zamlynny
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Mary Struthers
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Ann E. Weber
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| | - Scott D. Edmondson
- Early Development and Discovery Sciences, Merck and Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States
| |
Collapse
|
5
|
Perrone MG, Scilimati A. β3-Adrenoceptor ligand development history through patent review. Expert Opin Ther Pat 2011; 21:505-36. [DOI: 10.1517/13543776.2011.561316] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Morriello GJ, Wendt HR, Bansal A, Salvo JD, Feighner S, He J, Hurley AL, Hreniuk DL, Salituro GM, Reddy MV, Galloway SM, McGettigan KK, Laws G, McKnight C, Doss GA, Tsou NN, Black RM, Morris J, Ball RG, Sanfiz AT, Streckfuss E, Struthers M, Edmondson SD. Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists. Bioorg Med Chem Lett 2011; 21:1865-70. [DOI: 10.1016/j.bmcl.2010.12.087] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2010] [Revised: 12/14/2010] [Accepted: 12/16/2010] [Indexed: 11/25/2022]
|
7
|
Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles. Bioorg Med Chem Lett 2010; 20:1895-9. [PMID: 20181479 DOI: 10.1016/j.bmcl.2010.01.130] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2009] [Revised: 01/26/2010] [Accepted: 01/28/2010] [Indexed: 11/21/2022]
Abstract
A series of amide derived beta(3)-adrenergic receptor (AR) agonists is described. The discovery and optimization of several series of compounds derived from 1, is used to lay the SAR foundation for second generation beta(3)-AR agonists for the treatment of overactive bladder.
Collapse
|
8
|
Senthil Kumar P, Bharatam PV. Comparative 3D QSAR study on β(1)-, β(2)-, and β(3)-adrenoceptor agonists. Med Chem Res 2009; 19:1121-1140. [PMID: 21170122 PMCID: PMC2988205 DOI: 10.1007/s00044-009-9257-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2009] [Accepted: 09/02/2009] [Indexed: 11/15/2022]
Abstract
A quantitative structure–activity relationship study of tryptamine-based derivatives of β1-, β2-, and β3-adrenoceptor agonists was conducted using comparative molecular field analysis (CoMFA). Correlation coefficients (cross-validated r2) of 0.578, 0.595, and 0.558 were obtained for the three subtypes, respectively, in three different CoMFA models. All three CoMFA models have different steric and electrostatic contributions, implying different requirements inside the binding cavity. The CoMFA coefficient contour plots of the three models and comparisons among these plots provide clues regarding the main chemical features responsible for the biological activity variations and also result in predictions which correlate very well with the observed biological activity. Based on the analysis, a summary regeospecific description of the requirements for improving β-adrenoceptor subtype selectivity is given.
Collapse
Affiliation(s)
- P Senthil Kumar
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, (NIPER), Sector 67, S. A. S. Nagar, Mohali, 160 062 India
| | | |
Collapse
|
9
|
|
10
|
Frija LMT, Reva ID, Gómez-Zavaglia A, Cristiano MLS, Fausto R. UV-induced photochemistry of matrix-isolated 1-phenyl-4-allyl-tetrazolone. Photochem Photobiol Sci 2007; 6:1170-6. [PMID: 17973049 DOI: 10.1039/b703961a] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The photochemistry and molecular structure of 1-phenyl-4-allyl-tetrazolone (PAT) was studied by FT-IR matrix isolation spectroscopy and DFT(B3LYP)/6-311++G(d,p) calculations. The spectrum of matrix-isolated PAT monomers agrees well with the sum spectrum of three conformers predicted theoretically. UV irradiation (lambda > 235 nm) of matrix-isolated PAT induces three types of photofragmentation: (1) production of phenylazide and allyl-isocyanate, with phenylazide then losing N(2) to yield 1-aza-1,2,4,6-cycloheptatetraene; (2) formation of phenyl-isocyanate and allylazide; (3) N(2) elimination leading to formation of 1-allyl-2-phenyldiaziridin-3-one; this compound partially reacts further to form 1-allyl-1H-benzoimidazol-2(3H)-one. The observed photochemistry of the matrix-isolated PAT is distinct from the preferred photochemical fragmentation in solution, where 3,4-dihydro-3-phenylpyrimidin-2(1H)-one is produced as the primary photoproduct.
Collapse
Affiliation(s)
- L M T Frija
- Department of Chemistry and Biochemistry, F.C.T., and CCMAR, University of Algarve, Campus de Gambelas, 8005-039, Faro, Portugal
| | | | | | | | | |
Collapse
|
11
|
Gómez-Zavaglia A, Reva I, Frija L, Cristiano M, Fausto R. Photochemistry of 1-phenyl-tetrazolone isolated in solid argon. J Photochem Photobiol A Chem 2006. [DOI: 10.1016/j.jphotochem.2005.08.021] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Hanumantharao P, Sambasivarao SV, Soni LK, Gupta AK, Kaskhedikar SG. QSAR analysis of thiazole benzenesulfonamide substituted 3-pyridylethanolamines as beta3-adrenergic receptor agonist. Bioorg Med Chem Lett 2005; 15:3167-73. [PMID: 15908203 DOI: 10.1016/j.bmcl.2005.03.119] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2005] [Revised: 03/28/2005] [Accepted: 03/31/2005] [Indexed: 11/23/2022]
Abstract
A quantitative structure-activity relationship study on a series of substituted benzene sulfonamide-3-pyridylethanolamines with beta3-adrenergic receptor agonist activity was made using a combination of various physiochemical descriptors. Several significant equations with good co-efficients of correlation (0.930) were obtained; the two models were selected using predictive ability of equations for test set. Both models highlight some common important structural features, that is, high electrostatic potential energy and the lipophilic nature of the molecule, favorable for beta3-adrenergic receptor agonist activity.
Collapse
Affiliation(s)
- P Hanumantharao
- Molecular Modelling Study Group, CADD Laboratory, Department of Pharmacy, S.G.S.I.T.S., 23 Park Road, Indore 452003, M.P., India
| | | | | | | | | |
Collapse
|
13
|
Hu B, Jennings LL. Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes. PROGRESS IN MEDICINAL CHEMISTRY 2003; 41:167-94. [PMID: 12774694 DOI: 10.1016/s0079-6468(02)41005-3] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Affiliation(s)
- Baihua Hu
- Wyeth Research, P.O. Box 42528, Philadelphia, PA 19101, USA
| | | |
Collapse
|
14
|
Jagodziński TS. Thioamides as useful synthons in the synthesis of heterocycles. Chem Rev 2003; 103:197-227. [PMID: 12517184 DOI: 10.1021/cr0200015] [Citation(s) in RCA: 354] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Tadeusz S Jagodziński
- Institute of Chemistry and Environmental Protection, Department of Organic Chemistry, Technical University of Szczecin, PL-71-065 Szczecin, Aleja Piastów 42, Poland.
| |
Collapse
|
15
|
Stearns RA, Miller RR, Tang W, Kwei GY, Tang FS, Mathvink RJ, Naylor EM, Chitty D, Colandrea VJ, Weber AE, Colletti AE, Strauss JR, Keohane CA, Feeney WP, Iliff SA, Chiu SHL. The pharmacokinetics of a thiazole benzenesulfonamide beta 3-adrenergic receptor agonist and its analogs in rats, dogs, and monkeys: improving oral bioavailability. Drug Metab Dispos 2002; 30:771-7. [PMID: 12065435 DOI: 10.1124/dmd.30.7.771] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The pharmacokinetics and oral bioavailability of (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethylphenyl]thiazol-2-yl]benzenesulfonamide (1), a 3-pyridyl thiazole benzenesulfonamide beta3-adrenergic receptor agonist, were investigated in rats, dogs, and monkeys. Systemic clearance was higher in rats (approximately 30 ml/min/kg) than in dogs and monkeys (both approximately 10 ml/min/kg), and oral bioavailability was 17, 27, and 4%, respectively. Since systemic clearance was 25 to 40% of hepatic blood flow in these species, hepatic extraction was expected to be low, and it was likely that oral bioavailability was limited either by absorption or a large first-pass effect in the gut. The absorption and excretion of 3H-labeled 1 were investigated in rats, and only 28% of the administered radioactivity was orally absorbed. Subsequently, the hepatic extraction of 1 was evaluated in rats (30%) and monkeys (47%). The low oral bioavailability in rats could be explained completely by poor oral absorption and hepatic first-pass metabolism; in monkeys, oral absorption was either less than in rats or first-pass extraction in the gut was greater. In an attempt to increase oral exposure, the pharmacokinetics and oral bioavailability of two potential prodrugs of 1, an N-ethyl [(R)-N-[4-[2-[ethyl[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide; 2] and a morpholine derivative [(R)-N-[4-[2-[2-(3-pyridinyl)morpholin-4-yl]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)- phenyl]thiazol-2-yl]benzenesulfonamide; 3], were evaluated in monkeys. Conversion to 1 was low (<3%) with both derivatives, and neither entity was an effective prodrug, but the oral bioavailability of 3 (56%) compared with 1 (4%) was significantly improved. The hypothesis that the increased oral bioavailability of 3 was due to a reduction in hydrogen bonding sites in the molecule led to the design of (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-2-yl)ethyl]amino]ethyl]phenyl]-4-[4-(4-trifluoromethylphenyl)thiazol-2-yl]benzenesulfonamide (4), a 2-pyridyl beta3-adrenergic receptor agonist with improved oral bioavailability in rats and monkeys.
Collapse
Affiliation(s)
- Ralph A Stearns
- Department of Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Mathvink RJ, Tolman JS, Chitty D, Candelore MR, Cascieri MA, Colwell LF, Deng L, Feeney WP, Forrest MJ, Hom GJ, MacIntyre DE, Miller RR, Stearns RA, Tota L, Wyvratt MJ, Fisher MH, Weber AE. Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. J Med Chem 2000; 43:3832-6. [PMID: 11052788 DOI: 10.1021/jm000286i] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
As part of our investigation into the development of orally bioavailable beta(3) adrenergic receptor agonists, we have identified a series of pyridylethanolamine analogues possessing a substituted thiazole benzenesulfonamide pharmacophore that are potent human beta(3) agonists with excellent selectivity against other human beta receptor subtypes. Several of these compounds also exhibited an improved pharmacokinetic profile in dogs. For example, thiazole sulfonamide 2e (R = 4-F(3)C-C(6)H(4)) is a potent full beta(3) agonist (EC(50) = 3.6 nM, 94% activation) with >600-fold selectivity over the human beta(1) and beta(2) receptors, which also displays good oral bioavailability in several mammalian species, as well as an extended duration of action.
Collapse
Affiliation(s)
- R J Mathvink
- Merck Research Laboratories, Rahway, New Jersey 07065, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|